{"id":1806,"date":"2016-08-26T15:43:00","date_gmt":"2016-08-26T15:43:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-financial-results-in-the-first-half-year-of-2016\/"},"modified":"2022-06-30T15:45:42","modified_gmt":"2022-06-30T15:45:42","slug":"grindeks-financial-results-in-the-first-half-year-of-2016","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-financial-results-in-the-first-half-year-of-2016\/","title":{"rendered":"Par Grindeks rezult\u0101tiem 2016. gada pirmaj\u0101 pusgad\u0101"},"content":{"rendered":"\n<p>\u0160odien, 26. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2016. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2016. gada pirmaj\u0101 pusgad\u0101 bija 46,4 milj. eiro, kas ir par 2,6 milj. eiro vai par 5,9% vair\u0101k nek\u0101 2015. gada pirmaj\u0101 pusgad\u0101.<\/p>\n\n\n\n<p>Savuk\u0101rt koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2016. gada pirmaj\u0101 pusgad\u0101 bija 4,2 milj. eiro, kas, sal\u012bdzinot ar 2015. gada pirmo pusgadu, ir palielin\u0101jusies par 1,0 milj. eiro vai 32,4%. Bruto pe\u013c\u0146as rentabilit\u0101te 2016. gada pirmaj\u0101 pusgad\u0101 bija 51,1%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija 9,2%. 2016. gada pirmaj\u0101 pusgad\u0101 Koncerna sara\u017eot\u0101 produkcija eksport\u0113ta uz 64 pasaules valst\u012bm kopum\u0101 par 41,5 milj. eiro, kas ir par 1,7 milj. eiro vai par 4,2% vair\u0101k nek\u0101 2015. gada pirmaj\u0101 pusgad\u0101.<\/p>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2016. gada pirmaj\u0101 pusgad\u0101 bija 42,5 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 perioda pirmo pusgadu, par 3,4 milj. eiro vai 8,7%. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2016. gada pirmaj\u0101 pusgad\u0101 sasniedza 23,8 milj. eiro, kas ir par 0,3 milj. eiro vai 1,2% vair\u0101k nek\u0101 2015. gada pirmaj\u0101 pusgad\u0101. Nov\u0113rt\u0113jot iesp\u0113jamos val\u016btas riskus, Grindeks savu darb\u012bbu Vidus\u0101zijas valst\u012bs \u0161\u012b gada pirmaj\u0101 pusgad\u0101 ierobe\u017eoja, t\u0101d\u0113j\u0101di, samazinot eksporta apjomu uz \u0161\u012bm valst\u012bm. Sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, iev\u0113rojam\u0101kais p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Krievij\u0101 par 25%, Uzbekist\u0101n\u0101 par 18%, Moldov\u0101 par 17% un Turkmenist\u0101n\u0101 par 15%.<\/p>\n\n\n\n<p>Pateicoties biznesa diversifik\u0101cijas strat\u0113\u0123ijai un darb\u012bbas att\u012bst\u012bbai jaunos tirgos, p\u0101rdo\u0161anas apjoms Baltijas un cit\u0101s valst\u012bs 2016. gada pirmaj\u0101 pusgad\u0101 sasniedza 18,6 milj. eiro, kas ir par 3,1 milj. eiro vai 20,1% vair\u0101k nek\u0101 2015. gada pirmaj\u0101 pusgad\u0101. P\u0101rdo\u0161anas apjoms Horv\u0101tij\u0101, sal\u012bdzinot ar 2015. gada pirmo pusgadu, ir palielin\u0101jies 7,6 reizes, Sp\u0101nij\u0101 \u2013 4,0 reizes, Kan\u0101d\u0101 \u2013 1,8 reizes, savuk\u0101rt Ung\u0101rij\u0101 un Somij\u0101 palielin\u0101jies par 36%. P\u0101rdo\u0161anas apjoms Latvij\u0101 \u0161\u012b gada pirmaj\u0101 pusgad\u0101 sasniedza 3,8 milj. eiro, kas, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, ir palielin\u0101jies par 0,9 milj. eiro vai par 32,5%. Iev\u0113rojam p\u0101rdo\u0161anas apjoma pieaugums \u0161\u012b gada pirmaj\u0101 pusgad\u0101, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, bija ar\u012b p\u0101r\u0113j\u0101s Baltijas valst\u012bs \u2013 Lietuv\u0101 par 17% un Igaunij\u0101 par 16%.<\/p>\n\n\n\n<p>2016. gada pirmaj\u0101 pusgad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 3,2 milj. eiro, kas ir par 0,8 milj. eiro vai 20,4% maz\u0101k nek\u0101 2015. gada pirmaj\u0101 pusgad\u0101. \u0160aj\u0101 period\u0101 liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tikai veikts uz ES valst\u012bm, ASV, Austr\u0101liju un Jap\u0101nu. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2016. gada pirmaj\u0101 pusgad\u0101 bija oksitoc\u012bns, zopiklons, droperidols, pimobend\u0101ns un detomid\u012bns.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eAtskatoties uz paveikto \u0161\u012b gada pirmaj\u0101 pusgad\u0101, v\u0113los izcelt m\u016bsu pan\u0101kumus Baltijas un cit\u0101s Eiropas Savien\u012bbas valst\u012bs, kur esam sasniegu\u0161i stabilu p\u0101rdo\u0161anas apjoma pieaugumu. Tas ir m\u0113r\u0137tiec\u012bga un ilgsto\u0161a darba rezult\u0101ts, k\u0101 ar\u012b apliecin\u0101jums efekt\u012bv\u0101m m\u0101rketinga un p\u0101rdo\u0161anas aktivit\u0101t\u0113m. Koncentr\u0113\u0161an\u0101s uz stabiliem, k\u0101 ar\u012b jauniem tirgiem un produktu kl\u0101sta papla\u0161in\u0101\u0161ana pal\u012bdz mums stiprin\u0101t tirgus poz\u012bcijas un konkur\u0113tsp\u0113ju\u201d.<\/p>\n\n\n\n<p><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_rezult%C4%81ti_2016_gada_pirmaja_pusgada.pdf\" target=\"_blank\" rel=\"noopener\"><\/a><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_rezult%C4%81ti_2016_gada_pirmaja_pusgada.pdf\" target=\"_blank\" rel=\"noopener\">Grindeks 2016. gada 1. pusgada nerevid\u0113ts finan\u0161u p\u0101rskats (404 KB)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160odien, 26. august\u0101, akciju sabiedr\u012bbas Grindeks \u201eNasdaq Riga\u201d iesniegtie 2016. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2016. gada pirmaj\u0101 pusgad\u0101&#8230;<\/p>\n","protected":false},"author":3,"featured_media":1803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1806"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/1803"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}